Winkelstein J A
Rev Infect Dis. 1981 Mar-Apr;3(2):289-98. doi: 10.1093/clinids/3.2.289.
In recent years there has been a growing realization that the complement systems plays an important role in the host's defense against infection and that it plays an especially critical role in both natural and acquired immunity to Streptococcus pneumoniae. The terminal components of the complement system, C3-C9, are responsible for most protective functions of the complement system. However, in order to subserve their protective functions, C3-C9 must first be activated. In vitro studies have shown that pneumococci are able to activate the terminal components of complement, C3-C9, by at least two different mechanisms, the classical and alternative pathways. Regardless of the pathway of their activation, C3-C9 produce anaphylatoxic, chemotactic, and opsonic activities in serum, each of which has the potential to play an important protective role in pneumococcal infections. Studies with experimental animals and the experience gained from study of complement deficiencies in humans have each fulfilled the promise of the in vitro studies by demonstrating that the complement system plays a biologically significant role in vivo in the host's defense against S. pneumoniae.
近年来,人们越来越认识到补体系统在宿主抵御感染中发挥着重要作用,并且在对肺炎链球菌的天然免疫和获得性免疫中都起着尤为关键的作用。补体系统的终末成分C3 - C9负责补体系统的大部分保护功能。然而,为了发挥其保护功能,C3 - C9必须首先被激活。体外研究表明,肺炎球菌能够通过至少两种不同机制激活补体终末成分C3 - C9,即经典途径和替代途径。无论其激活途径如何,C3 - C9在血清中产生过敏毒素、趋化和调理活性,每一种活性都有可能在肺炎球菌感染中发挥重要的保护作用。对实验动物的研究以及从对人类补体缺陷的研究中获得的经验,都通过证明补体系统在宿主体内抵御肺炎链球菌的防御中发挥生物学上的重要作用,实现了体外研究的预期。